Metabolic syndrome and colorectal adenoma risk: A systematic review and meta?analysis - 28/10/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 11 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
Whether metabolic syndrome is a risk factor of colorectal adenoma has spurred debate. We systematically meta-analyzed all clinical studies associated with metabolic syndrome (MetS)/metabolic components and colorectal adenoma risk and quantified the dose-response association between them, aiming to provide more clues for better decision-making.
Methods |
We searched PubMed, EMBASE, and Cochrane Library through June 2020 for clinical studies of MetS and colorectal adenoma risk. RevMan 5.3 software and STATA 12.0 software were employed for meta-analysis.
Results |
Seventeen studies representing 44,336 participants were eligible for analysis. The overall meta-analysis showed that MetS patients had increased risk of colorectal adenoma (OR: 1.39, 95% CI 1.24–1.57; P < 0.05). Dose-response analysis presented that every increased number of Mets components was associated with a 8% increment of colorectal adenoma risk(OR: 1.08; 95% CI: 1.04–1.11). Subgroup analysis by age revealed a higher colorectal adenoma risk in MetS patients 50 years or older (OR 1.46; 95% CI 1.21–1.76; P < 0.0001), rather than MetS patients younger than 50 years old (OR 1.23; 95% CI 0.95–1.59; P = 0.11).When stratified by sex, the analysis revealed a higher risk of colorectal adenoma in male MetS patients (OR 1.32; 95% CI 1.15–1.53; P = 0.0001), rather than females (OR 1.65; 95% CI 0.90–3.02; P = 0.10). The analysis split by adenoma location showed that the right colon (OR 1.35; 95% CI 1.04–1.75; P = 0.03), instead of the left colon (OR 1.16; 95% CI 0.84–1.59; P = 0.37) or rectum(OR 1.26; 95% CI 0.89–1.78; P = 0.20), was the predilection site associated with increased colorectal adenoma risk in MetS patients.
Conclusions |
Overall, our meta-analysis showed that MetS was associated with a higher risk of colorectal adenoma. MetS patients, especially old (≥50 years) male patients, should be a risk population for colorectal adenoma screening so that they can benefit from behavioural interventions that can help prevent the development of colorectal cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Metabolic syndrome, Metabolic components, Colorectal adenoma, Meta-analysis, Risk
Plan
| Acknowledgements: The authors are grateful to Wei Liu for proofreading this manuscript. |
|
| Conflict of interests: The authors declared that they have no conflicts of interest to this paper. |
|
| Ethical approval: This article did not contain any studies with human participants or animals performed by any of the authors. |
|
| Informed consent: Informed consent was not necessary for this meta-analysis. |
|
| Funding: No funding was received. |
Vol 45 - N° 5
Article 101749- septembre 2021 Retour au numéro
Article précédent
- The role of miRNA125b in the progression of hepatocellular carcinoma
- Minghao Yang, Sheng Wei, Huiyong Zhao, Dachen Zhou, Xiao Cui
- Inverted colonic diverticulum (ICD): report of two cases and literature review of a not that unusual endoscopic challenge
- Francesco Cocomazzi, Sonia Carparelli, Rossella Cubisino, Arcangela Patrizia Giuliani, Fabrizio Bossa, Giuseppe Biscaglia, Paola Parente, Angelo Andriulli, Francesco Perri, Marco Gentile
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?